You searched for "infections"

1916 results found

High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema

The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...

Learning from litigation: ocular drug toxicity

Being the subject of litigation is stressful and upsetting. Having to look back over your previous decisions and justify the care you delivered in good faith can be difficult. Sadly, we all live with the sword of Damocles above us...

Short-term effects of intravitreal bevacizumab on the cornea

Bevacizumab has been extensively used to treat macula oedema and neovascularisation of the retina and it has also been useful in the management of corneal neovascular diseases. This prospective study aimed to provide more information on the effect bevacizumab may...

Minimally Invasive Glaucoma Surgery – A Practical Guide

The treatment of patients with mild to moderate glaucoma has evolved rapidly in the last decade. Traditionally, medical and laser treatments were the mainstay of therapy for this group of patients. Trabeculectomy, non-penetrating surgery and glaucoma drainage implants were reserved...

Learnings and trends in the management of open-angle and angle-closure glaucoma

To be truly disruptive, newer technologies need to offer a quality of life benefit over medication to a broad population of glaucoma sufferers. Evidence and converging trends in medical and surgical management of glaucoma were explored in counterpoint discussions and...

Ranibizumab for the treatment of age-related macular degeneration

This multicentre randomised prospective open label study compared 0.5 versus 2mg of ranibizumab in patients with submacular retinal pigment epithelial (RPE) detachment due to age-related macular degeneration. Four treatment regimens were used for the two strengths either monthly for 12...

Intravitreal functional plasminogen in branch retinal vein occlusion

Branch retinal vein occlusion (BRVO) is the second most common vascular disorder of the eye. Intravitreal injections of anti-VEGF agents and corticosteroids have proven efficacy. Posterior vitreous cortex (PVC) adhesion has been shown to support the development of retinal vein...

Acute dacryoadenitis secondary to COVID-19

Acute dacryoadenitis is defined as the rapid onset of discomfort and swelling of the lacrimal gland, classically giving rise to an S-shaped ptosis [1]. Dacryoadenitis is the most common cause of a painful mass in the lacrimal gland in young...

10 daily habits damaging your eyesight and changes you can make to remedy against them

Following World Glaucoma Day on 12 March this year, it is vital that the longevity of our vision is always a priority. However, many of our daily habits contribute to the onset of glaucoma and vision loss.

Injection of methotrexate into silicone oil-filled eyes for grade C PVR

Methotrexate (MTX) is an antineoplastic antimetabolite with immunosuppressant properties. Folate antagonism is known to contribute to the antiproliferative effects of MTX, and release of adenosine from cells and inhibition of polyamines may explain its anti-inflammatory effects. These activities contribute to...

From novice to overnight on-calls: developing an ophthalmology bootcamp to ease the learning curve for new trainees

Introduction My first ophthalmology on-call was nine years ago and it was a fairly traumatic experience. I was an FY2 in a Welsh district general hospital and I was on my own – at least, that’s how it felt to...

The management of antiplatelets and anticoagulation in elective ophthalmic surgery

Clinical scenario: A 57-year-old gentleman who is scheduled to have Mohs micrographic surgery and reconstruction for a medial canthal basel cell carcinoma (BCC) has been started on aspirin and clopidogrel following a coronary stent three weeks ago. Does the antiplatelet...